BioMarin Pharma (BMRN) – Major News
-
BioMarin Pharma (BMRN) Tops Q1 EPS by 39c ; Offers Guidance
-
BioMarin Pharma (BMRN) Tops Q4 EPS by 29c ; Offers Guidance
-
Activist Investor Elliott Takes Stake In Biomarin Pharmaceutical (BMRN), In Talks With Company About Its Future - Reuters
-
BioMarin Pharma (BMRN) Tops Q3 EPS by 23c; offers guidance
-
BioMarin Pharma (BMRN) Tops Q2 EPS by 31c, Offers Guidance
-
BioMarin Pharma (BMRN) Tops Q1 EPS by 39c
-
BioMarin Pharma (BMRN) Tops Q4 EPS
-
BioMarin Pharma (BMRN) Misses Q3 EPS by 2c
-
BioMarin Pharma (BMRN) Tops Q2 EPS by 12c, Offers Guidance
-
BioMarin Pharma (BMRN) Tops Q1 EPS by 46c
-
BioMarin Pharma (BMRN) Reports In-Line Q4 EPS
-
BioMarin Pharma (BMRN) Tops Q3 EPS by 4c
-
BioMarin Pharma (BMRN) Tops Q2 EPS by 18c
-
BioMarin Pharma (BMRN) Tops Q1 EPS by 19c, Offers FY Guidance
-
BioMarin Pharma (BMRN) Tops Q4 EPS by 31c
-
BioMarin Pharma (BMRN) Tops Q3 EPS, Lowers FY Revenue Guidance
-
BioMarin Pharma (BMRN) Misses Q2 EPS by 5c, Revenue Beats
-
BioMarin Pharma (BMRN) Tops Q1 EPS by 39c, Revs Beat; Trims FY Rev Outlook
-
BioMarin Pharma (BMRN) Tops Q4 EPS by 17c, Offers FY Guidance
-
BioMarin Pharma (BMRN) Tops Q3 Revenue
-
BioMarin Pharma (BMRN) Q2 Revenues Miss; Reaffirms FY Revs
-
BioMarin Pharma (BMRN) Misses Q1 EPS by 14c
-
BioMarin Pharma (BMRN) Posts Q4 Loss of $0.03/Share
-
BioMarin Pharma (BMRN) Tops Q3 EPS by 15c, Offers Guidance
-
BioMarin Pharma (BMRN) Tops Q2 EPS by 8c, Affirms FY Revenue Guidance, Lowers R&D Expense Guidance
-
BioMarin Pharma (BMRN) Misses Q1 EPS by 8c
-
BioMarin Pharma (BMRN) Misses Q4 EPS by 7c
-
BioMarin Pharma (BMRN) Tops Q3 EPS by 5c
-
BioMarin Pharma (BMRN) Reports In-Line Q2 EPS
-
BioMarin Pharma (BMRN) Tops Q1 EPS by 20c
-
BioMarin Pharma (BMRN) Posts Q4 Loss of $0.53
-
BioMarin Pharma (BMRN) Tops Q3 EPS by 13c, Revenue Misses
-
BioMarin Pharma's (BMRN) Q2 Revenue Tops Views
-
BioMarin Pharma (BMRN) Tops Q1 EPS by 32c, Offers Guidance
-
BioMarin Pharma (BMRN) Misses Q4 EPS Views
-
BioMarin Pharma (BMRN) Tops Q3 EPS by 5c; Raises Outlook
-
BioMarin Pharma (BMRN) Tops Q2 EPS by 2c, FY Guidance Unchanged
-
BioMarin Pharma (BMRN) Tops Q4 EPS by 12c
-
BioMarin Pharma (BMRN) to Acquire Prosensa (RNA) for $17.75/Share
-
BioMarin Pharma (BMRN) Tops Q3 EPS by 6c
-
BioMarin Pharma (BMRN) Lowers FY14 Revenue Forecast
-
BioMarin (BMRN) Tops Q2 EPS by 18c, Sells riority Review Voucher for $67.5 Million
-
BioMarin Pharmaceuticals, Inc. (BMRN) Reports Q4 Loss of 11c/sh
-
BioMarin's (BMRN) Vimizim Wins Backing of FDA Panel
-
BioMarin Pharma (BMRN) Posts Q3 GAAP Loss of 38c/Share
-
BioMarin Pharma (BMRN) Surges as Roche May Make Bid (ALXN)
-
BioMarin Pharmaceuticals, Inc. (BMRN) Tops Q2 EPS by 13c
-
BioMarin Pharmaceuticals, Inc. (BMRN) Misses Q1 EPS by 2c
-
BioMarin Pharmaceuticals, Inc. (BMRN) Posts Q4 GAAP Loss of 43c/Share; Guides FY13
-
BioMarin Pharmaceuticals, Inc. (BMRN) Tops Q3 EPS by 16c
Back to BMRN Stock Lookup